JP7672720B2 - 心筋幹／前駆細胞の作製方法及び心筋線維化抑制方法 - Google Patents

心筋幹／前駆細胞の作製方法及び心筋線維化抑制方法 Download PDF

Info

Publication number
JP7672720B2
JP7672720B2 JP2022557440A JP2022557440A JP7672720B2 JP 7672720 B2 JP7672720 B2 JP 7672720B2 JP 2022557440 A JP2022557440 A JP 2022557440A JP 2022557440 A JP2022557440 A JP 2022557440A JP 7672720 B2 JP7672720 B2 JP 7672720B2
Authority
JP
Japan
Prior art keywords
cardiomyocytes
rock inhibitor
treated
cells
tgfβ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022557440A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022080455A1 (https=
Inventor
麻生 村中
孝広 落谷
ヴィラ マルタ プリエト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DA VINCI UNIVERSALE CO., LTD.
Original Assignee
DA VINCI UNIVERSALE CO., LTD.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DA VINCI UNIVERSALE CO., LTD. filed Critical DA VINCI UNIVERSALE CO., LTD.
Publication of JPWO2022080455A1 publication Critical patent/JPWO2022080455A1/ja
Priority to JP2025067532A priority Critical patent/JP2025106562A/ja
Priority to JP2025067533A priority patent/JP2025106563A/ja
Application granted granted Critical
Publication of JP7672720B2 publication Critical patent/JP7672720B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1315—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from cardiomyocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/54—Collagen; Gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022557440A 2020-10-14 2021-10-14 心筋幹／前駆細胞の作製方法及び心筋線維化抑制方法 Active JP7672720B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2025067532A JP2025106562A (ja) 2020-10-14 2025-04-16 心筋幹／前駆細胞の作製方法及び心筋線維化抑制方法
JP2025067533A JP2025106563A (ja) 2020-10-14 2025-04-16 心筋幹／前駆細胞の作製方法及び心筋線維化抑制方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020173581 2020-10-14
JP2020173581 2020-10-14
PCT/JP2021/038071 WO2022080455A1 (ja) 2020-10-14 2021-10-14 心筋幹／前駆細胞の作製方法及び心筋線維化抑制方法

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2025067532A Division JP2025106562A (ja) 2020-10-14 2025-04-16 心筋幹／前駆細胞の作製方法及び心筋線維化抑制方法
JP2025067533A Division JP2025106563A (ja) 2020-10-14 2025-04-16 心筋幹／前駆細胞の作製方法及び心筋線維化抑制方法

Publications (2)

Publication Number Publication Date
JPWO2022080455A1 JPWO2022080455A1 (https=) 2022-04-21
JP7672720B2 true JP7672720B2 (ja) 2025-05-08

Family

ID=81208122

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022557440A Active JP7672720B2 (ja) 2020-10-14 2021-10-14 心筋幹／前駆細胞の作製方法及び心筋線維化抑制方法
JP2025067533A Pending JP2025106563A (ja) 2020-10-14 2025-04-16 心筋幹／前駆細胞の作製方法及び心筋線維化抑制方法
JP2025067532A Pending JP2025106562A (ja) 2020-10-14 2025-04-16 心筋幹／前駆細胞の作製方法及び心筋線維化抑制方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2025067533A Pending JP2025106563A (ja) 2020-10-14 2025-04-16 心筋幹／前駆細胞の作製方法及び心筋線維化抑制方法
JP2025067532A Pending JP2025106562A (ja) 2020-10-14 2025-04-16 心筋幹／前駆細胞の作製方法及び心筋線維化抑制方法

Country Status (7)

Country Link
US (1) US20230374462A1 (https=)
EP (1) EP4215602A4 (https=)
JP (3) JP7672720B2 (https=)
CN (1) CN116806257A (https=)
CA (1) CA3195608A1 (https=)
TW (1) TW202227615A (https=)
WO (1) WO2022080455A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3062949T3 (en) * 2018-10-15 2026-04-14 Evia Life Sciences Inc Method for producing stem/precursor cells, by using low molecular weight compound, from cells derived from endodermal tissue or organ
CN116536255B (zh) * 2023-07-05 2023-09-12 夏同生物科技(苏州)有限公司 一种高效诱导肌肉干细胞的培养基及方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018225705A1 (ja) 2017-06-05 2018-12-13 テルモ株式会社 細胞培養物の製造方法
WO2020067439A1 (ja) 2018-09-27 2020-04-02 国立大学法人大阪大学 心筋細胞のシート化方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180273906A1 (en) * 2014-04-17 2018-09-27 Muhammad Ashraf Microvesicle and stem cell compositions for therapeutic applications
JP2018079714A (ja) 2016-11-14 2018-05-24 株式会社ケーヒン 車両用空調装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018225705A1 (ja) 2017-06-05 2018-12-13 テルモ株式会社 細胞培養物の製造方法
WO2020067439A1 (ja) 2018-09-27 2020-04-02 国立大学法人大阪大学 心筋細胞のシート化方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chu L. et al.，Naunyn Schmiedebergs Arch Pharmacol，2005年，Vol. 371，pp. 185-194
SATOH, S. et al.，Biochem. Biophys. Res. Commun.，2012年，Vol. 424，pp. 338-340
松浦 勝久，細胞シートを用いた心筋前駆細胞移植による梗塞後心筋修復の分子機序の解明，科学研究費補助金研究成果報告書，2011年

Also Published As

Publication number Publication date
US20230374462A1 (en) 2023-11-23
JP2025106563A (ja) 2025-07-15
EP4215602A4 (en) 2024-11-06
JP2025106562A (ja) 2025-07-15
CA3195608A1 (en) 2022-04-21
EP4215602A1 (en) 2023-07-26
JPWO2022080455A1 (https=) 2022-04-21
WO2022080455A1 (ja) 2022-04-21
TW202227615A (zh) 2022-07-16
CN116806257A (zh) 2023-09-26

Similar Documents

Publication Publication Date Title
JP2025106562A (ja) 心筋幹／前駆細胞の作製方法及び心筋線維化抑制方法
JP7097814B2 (ja) ヒト心室前駆細胞の生着のための遺伝子マーカー
Jiang et al. Transcriptional profiling of young and old mesenchymal stem cells in response to oxygen deprivation and reparability of the infarcted myocardium
JP7048977B2 (ja) コロニー形成培地及びその使用
JP2020534004A (ja) ヒト多能性幹細胞由来の胸腺オルガノイドのインビトロ生成
JP6648259B2 (ja) 向上された臍帯由来付着型幹細胞、その製造方法及びその用途
JP7568239B2 (ja) 幹細胞由来エクソソームを含む組成物及びその製造方法
JPWO2003038076A1 (ja) 不死化間葉系細胞及びその利用
WO2021054449A1 (ja) Ｌｂｍ、ｃｐｃ、ｏｐｃ、それらの調製方法及び品質管理方法、キット、移植材料並びに疾患モデル
JPWO2016148216A1 (ja) 肝細胞及び肝非実質細胞、並びにそれらの調製方法
US20070054397A1 (en) Adult cardiac uncommitted progenitor cells
CN110914412B (zh) 多巴胺能神经细胞的分离方法及包含利用其分离的多巴胺能神经细胞的用于治疗帕金森氏病的药剂学组合物
JP2007143554A (ja) 細胞移植方法及び試薬
JPWO2006078034A1 (ja) 心筋細胞への分化能を有する細胞
JP2022191370A (ja) 線維化抑制作用を有する細胞シート
US9969978B2 (en) Method for producing cardiomyocytes from human or mouse embryonic stem cells in a medium consisting of a serum-free medium and N2 supplement
JPWO2006093276A1 (ja) 心臓組織由来の多能性幹細胞
JP7298844B2 (ja) 細胞培養物の製造方法
JP6095272B2 (ja) 上皮系体性幹細胞の製造方法
HK40098156A (zh) 心肌干细胞/心肌前体细胞的制备方法及心肌纤维化抑制方法
WO2022153996A1 (ja) 間葉系幹細胞、抗炎症剤及び神経疾患治療剤
JP7373246B1 (ja) 心臓内幹細胞を含む細胞集団
JP2007014273A (ja) 肝組織・臓器及びその製造方法
WO2025178117A1 (ja) 破骨細胞への分化抑制に用いるための組成物
WO2023282338A1 (ja) 細胞播種剤及び細胞移植用基材

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230403

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20230627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241223

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250416

R150 Certificate of patent or registration of utility model

Ref document number: 7672720

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150